Literature DB >> 17113959

Olanzapine attenuates brain damage after focal cerebral ischemia in vivo.

Burak Yulug1, Aysegül Yildiz, Orkide Hüdaoglu, Erdinc Kilic, Ertugrul Cam, Wolf Rüdiger Schäbitz.   

Abstract

Atypical antipsychotic drugs are widely used in the treatment of schizophrenia. These agents are discovered to have some additional beneficial effects beyond their effectiveness as antipsychotic drugs. Among these initially unexpected effects are their potential effects as mood stabilizers in bipolar disorder and their efficacy in improving long-term outcome in schizophrenia. These effects recently raised the question whether these drugs may also have some neuroprotective effect in the brain. To examine this matter, in this study we evaluated the neuroprotective effect of olanzapine after permanent focal cerebral ischemia. Anaesthetized male C57BL/6j mice were submitted to permanent thread occlusion of the middle cerebral artery (MCA). Olanzapine (0.1 and 1 mg/kg) or vehicle was applied intraperitoneally just after permanent ischemia. Twenty-four hours after permanent ischemia, brain injury was evaluated by triphenyltetrazolium chloride staining (TTC). Olanzapine (0.1 and 1 mg/kg) showed significant neuroprotection after permanent focal cerebral ischemia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17113959     DOI: 10.1016/j.brainresbull.2006.09.018

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  12 in total

Review 1.  Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systematic review.

Authors:  Emilio Sacchetti; Cesare Turrina; Paolo Valsecchi
Journal:  Drug Saf       Date:  2010-04-01       Impact factor: 5.606

2.  Administration of haloperidol and risperidone after neurobehavioral testing hinders the recovery of traumatic brain injury-induced deficits.

Authors:  Ann N Hoffman; Jeffrey P Cheng; Ross D Zafonte; Anthony E Kline
Journal:  Life Sci       Date:  2008-08-31       Impact factor: 5.037

Review 3.  The neurotrophic and neuroprotective effects of psychotropic agents.

Authors:  Joshua Hunsberger; Daniel R Austin; Ioline D Henter; Guang Chen
Journal:  Dialogues Clin Neurosci       Date:  2009       Impact factor: 5.986

Review 4.  Early intervention in bipolar disorder, part II: therapeutics.

Authors:  Giacomo Salvadore; Wayne C Drevets; Ioline D Henter; Carlos A Zarate; Husseini K Manji
Journal:  Early Interv Psychiatry       Date:  2008-08       Impact factor: 2.732

5.  Olanzapine Reversed Brain Gene Expression Changes Induced by Phencyclidine Treatment in Non-Human Primates.

Authors:  Maureen V Martin; Karoly Mirnics; Laura K Nisenbaum; Marquis P Vawter
Journal:  Mol Neuropsychiatry       Date:  2015-07

6.  Olanzapine potentiates neuronal survival and neural stem cell differentiation: regulation of endoplasmic reticulum stress response proteins.

Authors:  S Kurosawa; E Hashimoto; W Ukai; S Toki; S Saito; T Saito
Journal:  J Neural Transm (Vienna)       Date:  2007-06-08       Impact factor: 3.575

7.  Post-stroke mortality, stroke severity, and preadmission antipsychotic medicine use--a population-based cohort study.

Authors:  Anders Prior; Thomas Munk Laursen; Karen Kjær Larsen; Søren Paaske Johnsen; Jakob Christensen; Grethe Andersen; Mogens Vestergaard
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

8.  Effect of different antipsychotic drugs on short-term mortality in stroke patients.

Authors:  Jen-Yu Wang; Cheng-Yi Wang; Chen-Hui Tan; Ting-Ting Chao; Yung-Sung Huang; Ching-Chih Lee
Journal:  Medicine (Baltimore)       Date:  2014-11       Impact factor: 1.889

9.  Post-stroke Movement Disorders: Clinical Manifestations and Pharmacological Management.

Authors:  Antonio Siniscalchi; Luca Gallelli; Angelo Labate; Giovanni Malferrari; Caterina Palleria; Giovambattista De Sarro
Journal:  Curr Neuropharmacol       Date:  2012-09       Impact factor: 7.363

10.  Cognitive-enhancing effects of aripiprazole: a case report.

Authors:  Armida Mucci; Giuseppe Piegari; Silvana Galderisi
Journal:  Clin Pract Epidemiol Ment Health       Date:  2008-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.